Trials / No Longer Available
No Longer AvailableNCT03554434
An Expanded Access Program for AM0010 (Pegilodecakin)
An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
Conditions
- Melanoma
- Prostate Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Carcinoma
- Non-small Cell Lung Carcinoma
- Solid Tumors
- Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AM0010 | AM0010 |
Timeline
- First posted
- 2018-06-13
- Last updated
- 2020-03-02
Source: ClinicalTrials.gov record NCT03554434. Inclusion in this directory is not an endorsement.